The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; none of the 18 sources its claims cite is checked for support yet.
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Open accessPublished version of a preprint
Abstract
A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies. Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation1. Proposed clinical applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk. Although most disease risk is polygenic in nature2–5, it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations. Here, we develop and validate genome-wide polygenic scores for five common diseases. The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, respectively. For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk6. We propose that it is time to contemplate the inclusion of polygenic risk prediction in clinical care, and discuss relevant issues. Genome-wide polygenic risk scores derived from GWAS data for five common diseases can identify subgroups of the population with risk approaching or exceeding that of a monogenic mutation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
25 Own result · 10 Not checked yet · 7 Own method · 3 Own interpretation · 2 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, even for our middle-aged study population, practicing clinicians could not identify the 8% of individuals at ≥3-fold risk based on GPSCAD in the absence of genotype information (Supplementary Table 8).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.5% of the population at ≥3-fold risk and the top 1% had 3.30-fold risk. (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 6.1% of the population at ≥3-fold risk and the top 1% had 4.63-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.2% of the population at ≥3-fold risk and the top 1% had 3.87-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This predictor performed equivalently well in the testing dataset, with AUC of 0.81.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plainn = 288,978- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results for CAD generalized to four other diseases: risk increased sharply in the right tail of the GPS distribution (Figure 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our testing dataset, 19.8% of participants were at ≥3-fold increased risk for at least one of the five diseases studied (Table 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“GPSCAD performed substantially better than two previously published polygenic scores for coronary artery disease that included 50 and 49,310 variants, respectively (Supplementary Table 7 and Supplementary Fig. 1).17,18”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [17] Tada, H. et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur. Heart J. 37, 561–567 (2016). source
- Not checked yetcites [18] Abraham, G. et al. Genomic prediction of coronary heart disease. Eur. Heart J. 37, 3267–3278 (2016). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 8
- Probably not a substantial claim. 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The predictors had AUC ranging from 0.79 – 0.81 in the validation set, with the best predictor (GPSCAD) involving 6,630,150 variants (Supplementary Table 1).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelationaln = 120,280- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Across the population, GPSCAD is normally distributed with the empirical risk of CAD rising sharply in the right tail of the distribution, from 0.8% in the lowest percentile to 11.1% in the highest percentile (Figure 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In order to analyze individuals with a relatively homogenous ancestry and owing to small percentages of non-British individuals, the present analysis was restricted to the white British ancestry individuals.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Whereas identifying carriers of rare monogenic mutations requires sequencing of specific genes and careful interpretation of the functional effects of mutations found, polygenic scores can be readily calculated for many diseases simultaneously, based on data from a single genotyping array.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our validation and testing was performed in the UK Biobank population.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These initial efforts were hampered by three challenges: (i) the small size of initial genome-wide association studies (GWAS), which affected the precision of the estimated impact of individual variants on disease risk; (ii) limited computational methods for creating GPS; and (iii) lack of large datasets needed to validate and test GPS.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results above show that, for a number of common diseases, polygenic risk scores can now identify a substantially larger fraction of the population than found by rare monogenic mutations, at comparable or greater disease risk.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The vast majority of common disease occurs in individuals without rare monogenic mutations.
In the paper
“Individuals who volunteered for the UK Biobank tended to be more healthy than the general population;27”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [27] Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In both cases, it is important to recognize that the risk associated with a high polygenic score may not reflect a single underlying mechanism, but rather the combined influence of multiple pathways.28”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [28] Khera, A. V. & Kathiresan, S. Is coronary atherosclerosis one disease or many? Setting realistic expectations for precision medicine. Circulation 135, 1005–1007 (2017). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, we previously showed that a high polygenic risk for CAD may be offset by either of two interventions: adherence to a healthy lifestyle or cholesterol-lowering therapy with statin medications.19–21”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [19] Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med. 375, 2349–2358 (2016). source
- Not checked yetcites [20] Mega, J. L. et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385, 2264–2271 (2015). source
- Not checked yetcites [21] Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135, 2091–2101 (2017). source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“UK Biobank samples were not included in any of the five discovery GWAS studies.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Polygenic score derivation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“An important example is the presence of a familial hypercholesterolemia mutation in 0.4% of the population, which confers an up to 3-fold increased risk for coronary artery disease (CAD).6”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [6] Abul-Husn, N. S. et al. Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science 354, pii: aaf7000 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Another example is the p.E508K missense mutation in HNF1A, with carrier frequency of 0.1% of the general population and 0.7% of Latinos,8 which confers up to 5-fold increased risk for type 2 diabetes.9”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [8] Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). source
- Not checked yetcites [9] Estrada, K. et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311, 2305–2314 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The vast majority of common disease occurs in individuals without rare monogenic mutations.
“Although ascertainment of monogenic mutations can be highly relevant for carriers and their families, the vast majority of disease occurs in those without such mutations.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, integrated models of PRS together with other lifestyle and clinical factors have enabled clinicians to more accurately quantify the risk of heart attack for patients;”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This enthusiasm is driven by observations that a polygenic burden of LDL-increasing SNPs can confer monogenic-equivalent risk of cardiovascular disease, with polygenic scores improving clinical models for risk assessment and statin prescription that can reduce coronary heart disease and improve healthcare delivery efficiency5–7.”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using polygenic scores, it is now possible to combine information from millions of genomic variants to identify people whose overall polygenic risk of coronary artery disease is as high as that of patients with monogenic lipid disorders such as familial hypercholesterolemia [23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, they have contributed new approaches to risk prediction for adverse phenotypes related to heart disease [21–23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
In the citing paper
“As described below, findings from GWAS have increasing translational impact through identification of novel therapeutic targets67, prioritization (and deprioritization) of existing ones68 and development of polygenic scores that quantify individual genetic risk69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“The development of robust polygenic scores for several common diseases has been catalysed by more precise per-variant effect estimates from larger GWAS datasets, improved algorithms for combining information across millions of single-nucleotide polymorphisms, and large-scale biobanks that support score validation69,146,147.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“For example, a genome-wide polygenic score for heart attack, incorporating 6.6 million variants, indicates that 5% of European-descent individuals have a risk of future cardiac events equivalent to that seen in those with less frequent monogenic forms of hypercholesterolaemia69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“This paper used large-scale genetic data to demonstrate the clinical potential of the polygenic scores that can be constructed for many common diseases, emphasizing that, in some situations, the lifetime risk of disease for those with the highest scores approaches that of established monogenic disease.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Statistical analysis within the testing dataset
“For each disease, the GPS with the best discriminative capacity in the testing dataset was calculated in the testing dataset of 288,278 participants”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationVos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Second-generation PLINK: rising to the challenge of larger and richer datasets
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015) · Gigascience · doi:10.1186/s13742-015-0047-8 · Cited by 12,709
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Self-citationCommon polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,006
Epigenomic Assessment of Cardiovascular Disease Risk and Interactions With Traditional Risk Metrics
Westerman, K. E., Fernández‐Sanlés, A., Patil, P., Sebastiani, P., Jacques, P. F., Starr, J. M., Deary, I. J., Liu, Q., Liu, S., Elosúa, R., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015299 · Cited by 52
Population Bias in Polygenic Risk Prediction Models for Coronary Artery Disease
Gola, D., Erdmann, J., Läll, K., Mägi, R., Müller‐Myhsok, B., Schunkert, H., & König, I. R. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.002932 · Cited by 52
Zebardast, N., Sekimitsu, S., Wang, J., Elze, T., Gharahkhani, P., Cole, B. S., Lin, M. M., Segrè, A. V., Wiggs, J. L., Aung, T., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.03.007 · Cited by 52
Karcher, N. R., Paul, S. E., Johnson, E. C., Hatoum, A. S., Baranger, D. A. A., Arpana Agrawal, A., Thompson, W. K., Barch, D. M., & Bogdan, R. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.06.012 · Cited by 55
Wu, G., Zhang, W., & Li, H. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112057 · Cited by 52
Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury
Mosedale, M., & Watkins, P. B. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01297 · Cited by 53
Genetic discovery and risk characterization in type 2 diabetes across diverse populations
Polfus, L. M., Darst, B. F., Highland, H. M., Sheng, X., Ng, M. C. Y., Below, J. E., Petty, L. E., Bien, S. A., Sim, X., Wang, W., et al. (2021) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100029 · Cited by 52
From personalised nutrition to precision medicine: the rise of consumer genomics and digital health
Moore, J. B. (2020) · Proceedings of The Nutrition Society · doi:10.1017/s0029665120006977 · Cited by 52
Human genetics and its impact on cardiovascular disease
Tada, H., Fujino, N., Hayashi, K., Kawashiri, M., & Takamura, M. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.09.005 · Cited by 57
Unsupervised Learning for Automated Detection of Coronary Artery Disease Subgroups
Flores, A. M., Schuler, A., Eberhard, A. V., Olin, J. W., Cooke, J. P., Leeper, N. J., Shah, N. H., & Ross, E. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021976 · Cited by 54
Girard, D., & Vandiedonck, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.991716 · Cited by 55
Jiang, G., Luk, A. O. Y., Tam, C. H. T., Lau, E. S. H., Ozaki, R., Chow, E., Kong, A. P. S., Lim, C. K. P., Lee, K. F., Siu, S. C., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003209 · Cited by 51
PUMAS: fine-tuning polygenic risk scores with GWAS summary statistics
Zhao, Z., Yi, Y., Song, J., Wu, Y., Zhong, X., Lin, Y., Hohman, T. J., Fletcher, J. M., & Lu, Q. (2021) · Genome biology · doi:10.1186/s13059-021-02479-9 · Cited by 52
Muse, E. D., & Topol, E. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.02.002 · Cited by 50
The evolution of group differences in changing environments
Harpak, A., & Przeworski, M. (2021) · PLOS Biology · doi:10.1371/journal.pbio.3001072 · Cited by 50
Roberts, R., Chang, C. C., & Hadley, T. D. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.09.004 · Cited by 54
Agrawal, S., Klarqvist, M. D. R., Emdin, C. A., Patel, A. P., Paranjpe, M. D., Ellinor, P. T., Philippakis, A., Ng, K., Batra, P., & Khera, A. V. (2021) · Patterns · doi:10.1016/j.patter.2021.100364 · Cited by 52
Self-citationTissue-specific multi-omics analysis of atrial fibrillation
Assum, I., Krause, J., Scheinhardt, M. O., Müller, C., Hammer, E., Börschel, C. S., Völker, U., Conradi, L., Geelhoed, B., Zeller, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-27953-1 · Cited by 51
Multiancestral polygenic risk score for pediatric asthma
Namjou, B., Lape, M., Małolepsza, E., DeVore, S. B., Weirauch, M. T., Dikilitas, O., Jarvik, G. P., Kiryluk, K., Kullo, I., Liu, C., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.03.035 · Cited by 50
Fuat, A., Adlen, E., Monane, M., Coll, R., Groves, S., Little, E., Wild, J., Kamali, F. J., Soni, Y., Haining, S. A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae004 · Cited by 50
Genetic testing in early-onset atrial fibrillation
Kany, S., Jurgens, S. J., Rämö, J. T., Christophersen, I. E., Rienstra, M., Chung, M. K., OLESEN, M. S., Ackerman, M. J., McNally, E. M., Semsarian, C., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae298 · Cited by 50
Self-citationAtrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes
Pulit, S. L., Weng, L.-C. C., McArdle, P. F., Trinquart, L., Choi, S. H., Mitchell, B. D., Rosand, J. M., de Bakker, P. I. W., Benjamin, E. J., Ellinor, P. T., et al. (2018) · Neurology Genetics · doi:10.1212/nxg.0000000000000293 · Cited by 51
Self-citationConnected Health Technology for Cardiovascular Disease Prevention and Management
Wongvibulsin, S., Martin, S. S., Steinhubl, S. R., & Muse, E. D. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0729-0 · Cited by 52
Polygenic Risk Scores: What Are They Good For?
Zheutlin, A. B., & Ross, D. A. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.04.007 · Cited by 49
The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
Chew, N., Chong, B., Ng, C. H., Kong, G., Chin, Y. H., Xiao, W., Lee, C. J. M., Dan, Y. Y., Muthiah, M. D., & Foo, R. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.971484 · Cited by 49
Pinzón-Espinosa, J., van der Horst, M. Z., Zinkstok, J., Austin, J., Aalfs, C. M., Batalla, A., Sullivan, P. F., Vorstman, J. A. S., & Luykx, J. J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02203-6 · Cited by 51
Nasal DNA methylation at three CpG sites predicts childhood allergic disease
van Breugel, M., Qi, C., Xu, Z., Pedersen, C. T., Petoukhov, I., Vonk, J. M., Gehring, U., Berg, M., Bügel, M., Carpaij, O. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35088-6 · Cited by 49
Addressing the challenges of polygenic scores in human genetic research
Novembre, J., Stein, C. M., Asgari, S., Gonzaga-Jauregui, C. G., Landstrom, A. P., Lemke, A. A., Li, J. Z., Mighton, C. E., Taylor, M. R., & Tishkoff, S. A. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.10.012 · Cited by 49
Shiffman, D., Louie, J. Z., Devlin, J. J., Rowland, C. M., & Mora, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22119 · Cited by 51
Márquez‐Luna, C., Gazal, S., Loh, P., Kim, S. S., Furlotte, N. A., Auton, A., & Price, A. L. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/375337 · Cited by 50
Albiñana, C., Grove, J., McGrath, J. J., Agerbo, E., Wray, N. R., Bulik, C. M., Nordentoft, M., HOUGAARD, D. M., Werge, T. M., Børglum, A. D., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.04.014 · Cited by 50
Personalized profiles for disease risk must capture all facets of health
McCarthy, M. I., & Birney, E. (2021) · Nature · doi:10.1038/d41586-021-02401-0 · Cited by 48
Why Do We Care More About Disease than Health?
Picard, M. A. (2022) · Phenomics · doi:10.1007/s43657-021-00037-8 · Cited by 51
Prostate cancer polygenic risk score and prediction of lethal prostate cancer
Klein, R. J., Vertosick, E., Sjoberg, D., Ulmert, D., Rönn, A., Häggström, C., Thysell, E., Hallmans, G., Dahlin, A., Stattin, P. E., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00266-8 · Cited by 51
Clark, K., Leung, Y. Y., Lee, W., Voight, B. F., & Wang, L. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220025 · Cited by 48
Monti, R., Eick, L., Hudjashov, G., Läll, K., Kanoni, S., Wolford, B. N., Wingfield, B., Pain, O., Wharrie, S., Jermy, B. S., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.06.003 · Cited by 52
An open-source framework for end-to-end analysis of electronic health record data
Heumos, L., Ehmele, P., Treis, T., zu Belzen, J. U., Roellin, E., May, L., Namsaraeva, A., Horlava, N., Shitov, V. A., Zhang, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03214-0 · Cited by 52
Harrison, J., Tallapragada, D. S. P., Baptist, A., Sharp, S. A., Bhaskar, S., Jog, K., Patel, K., Weedon, M. N., Chandak, G. R., Yajnik, C. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65317-1 · Cited by 48
Kember, R. L., Merikangas, A. K., Verma, S. S., Verma, A., Judy, R., Abecasis, G. R., Baras, A., Cantor, M., Coppola, G., Economides, A. N., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.06.026 · Cited by 48
O’Sullivan, J. W., Shcherbina, A., Justesen, J. M., Turakhia, M. P., Perez, M. V., Wand, H., Tcheandjieu, C., Clarke, S. L., Harrington, R. A., Rivas, M. A., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003168 · Cited by 48
A tool for translating polygenic scores onto the absolute scale using summary statistics
Pain, O., Gillett, A. C., Austin, J., Folkersen, L., & Lewis, C. M. (2022) · European Journal of Human Genetics · doi:10.1038/s41431-021-01028-z · Cited by 50
Family-GWAS reveals effects of environment and mating on genetic associations
Tan, T., Jayashankar, H., Guan, J., Nehzati, S. M., Mir, M., Bennett, M., Agerbo, E., Ahlskog, R., de Andrade Anapaz, V. P., Benonisdottir, S., et al. (2024) · doi:10.1101/2024.10.01.24314703 · Cited by 47
Mordi, I. R., Trucco, E., Syed, M. G., MacGillivray, T., Nar, A., Huang, Y. S., George, G., Hogg, S., Radha, V., Prathiba, V., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1124 · Cited by 47
Ayurgenomics-based frameworks in precision and integrative medicine: Translational opportunities
Mukerji, M. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.15 · Cited by 49
Early-onset atherosclerotic cardiovascular disease
Mousavi, I., Suffredini, J. M., Virani, S. S., Ballantyne, C. M., Michos, E. D., Misra, A., Saeed, A., & Jia, X. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae240 · Cited by 51
First myocardial infarction: risk factors, symptoms, and medical therapy
Nurmohamed, N. S., Ngo‐Metzger, Q., Taub, P. R., Ray, K. K., Figtree, G. A., Bonaca, M. P., Hsia, J. A., Angadageri, S., Earls, J. P., Rodríguez, F., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf390 · Cited by 49
Yaeger, K., Martini, M. L., Yaniv, G., Oermann, E. K., & Costa, A. B. (2019) · Health Policy and Technology · doi:10.1016/j.hlpt.2019.05.006 · Cited by 47
The role of genomics in global cancer prevention
Ginsburg, O., Ashton‐Prolla, P., Cantor, A., Mariosa, D., & Brennan, P. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0428-5 · Cited by 50
Genome‐wide association studies of structural birth defects: A review and commentary
Lupo, P. J., Mitchell, L. E., & Jenkins, M. M. (2019) · Birth Defects Research · doi:10.1002/bdr2.1606 · Cited by 46
Usova, E., Alieva, A. S., Yakovlev, A. N., Алиева, М. С., Prokhorikhin, A. A., Конради, А. О., Shlyakhto, E. V., Magni, P., Catapano, A. L., & Baragetti, A. (2021) · Biomolecules · doi:10.3390/biom11111597 · Cited by 52
Coronary Risk Estimation Based on Clinical Data in Electronic Health Records
Petrazzini, B. O., Chaudhary, K., Márquez‐Luna, C., Forrest, I. S., Rocheleau, G., Cho, J. H., Narula, J., Nadkarni, G. N., & Do, R. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.01.021 · Cited by 49
Goyal, S., Rani, J., Bhat, M. A., & Vanita, V. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.656 · Cited by 48
Gene therapy and genome editing for lipoprotein disorders
Gurevitz, C., Bajaj, A., Khera, A. V., Do, R., Schunkert, H., Musunuru, K., & Rosenson, R. S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf411 · Cited by 50
Self-citationTorske, T., Nærland, T., Bettella, F., Bjella, T. D., Malt, E. A., Høyland, A. L., Stenberg, N., Øie, M. G., & Andreassen, O. A. (2019) · Autism Research · doi:10.1002/aur.2207 · Cited by 48
Stahl, E. A., Roda, G., Dobbyn, A. L., Hu, J., Zhang, Z., Westerlind, H., Bonfiglio, F., Raj, T., Torres, J., Chen, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.04.063 · Cited by 46
Systemic sclerosis pathogenesis: contribution of recent advances in genetics
Orvain, C., Assassi, S., Avouac, J., & Allanore, Y. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000735 · Cited by 46
Lanfear, D. E., Luzum, J. A., She, R., Gui, H., Donahue, M., O’Connor, C. M., Adams, K. F., Wijk, S. S., Zeld, N., Maeder, M. T., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.007012 · Cited by 47
Pais, R., & Maurel, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061161 · Cited by 47
Merino, J., Guasch‐Ferré, M., Li, J., Chung, W., Hu, Y., Ma, B., Li, Y., Kang, J. H., Kraft, P. L., Liang, L., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003972 · Cited by 48
Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia
Trinder, M., Vikulova, D. N., Pimstone, S. N., Mancini, G. B. J., & Brunham, L. R. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.032 · Cited by 45
Including diverse and admixed populations in genetic epidemiology research
Caliebe, A., Ayele, F. T., Darst, B. F., Wang, X., Song, Y. E., Gui, J., Sebro, R., Balding, D. J., Saad, M., & Dubé, M. (2022) · Genetic Epidemiology · doi:10.1002/gepi.22492 · Cited by 46
Bigdeli, T. B., Voloudakis, G., Barr, P. B., Gorman, B. R., Genovese, G., Peterson, R. E., Burstein, D., Velicu, V. I., Li, Y., Gupta, R., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2742 · Cited by 49
Syed, M. G., Trucco, E., Mookiah, M. R. K., Lang, C. C., McCrimmon, R. J., Palmer, C. N. A., Pearson, E. R., Doney, A. S. F., & Mordi, I. R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02564-w · Cited by 45
Gola, D., Erdmann, J., Müller‐Myhsok, B., Schunkert, H., & König, I. R. (2020) · Genetic Epidemiology · doi:10.1002/gepi.22279 · Cited by 46
Omics and Cardiometabolic Disease Risk Prediction
Tahir, U. A., & Gerszten, R. E. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-042418-010924 · Cited by 45
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
Lin, W., Fordham, S. E., Hungate, E. A., Sunter, N. J., Elstob, C. J., Xu, Y., Park, C., Quante, A. S., Strauch, K., Gieger, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26551-x · Cited by 46
A Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics
Johnson, D., Wilke, M. A. P., Lyle, S. M., Kowalec, K., Jorgensen, A., Wright, G. E. B., & Drögemöller, B. I. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2520 · Cited by 47
Dornbos, P., Koesterer, R., Ruttenburg, A., Nguyen, T. T. H., Cole, J. B., Leong, A., Meigs, J. B., Florez, J. C., Rotter, J. I., Udler, M. S., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01200-1 · Cited by 51
The Genetic Basis of Thyroid Function: Novel Findings and New Approaches
Kuś, A., Chaker, L., Teumer, A., Peeters, R. P., & Medici, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz225 · Cited by 44
Polygenic Scores in Psychiatry: On the Road From Discovery to Implementation
Lewis, C. M., & Vassos, E. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220795 · Cited by 48
Cecile, A., Janssens, A. C. J. W., & Joyner, M. J. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.296103 · Cited by 44
Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making?
Lee, H., & Cleynen, I. (2019) · Cells · doi:10.3390/cells8060535 · Cited by 46
Ünlü, G., Qi, X., Gamazon, E. R., Melville, D. B., Patel, N., Rushing, A. R., Hashem, M., AlFaifi, A. Y., Chen, R., Li, B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0705-y · Cited by 47
Genome-Wide Polygenic Score and the Risk of Ischemic Stroke in a Prospective Cohort
Hachiya, T., Hata, J., Hirakawa, Y., Yoshida, D., Furuta, Y., Kitazono, T., Shimizu, A., & Ninomiya, T. (2020) · Stroke · doi:10.1161/strokeaha.119.027520 · Cited by 44
Artificial Intelligence (AI) in medicine as a strategic valuable tool
Larentzakis, A. V., & Lygerōs, N. (2021) · Pan African Medical Journal · doi:10.11604/pamj.2021.38.184.28197 · Cited by 45
Translational Medicine in the Era of Big Data and Machine Learning
Weintraub, W. S., Fahed, A. C., & Rumsfeld, J. S. (2018) · Circulation Research · doi:10.1161/circresaha.118.313944 · Cited by 47
Current clinical use of polygenic scores will risk exacerbating health disparities
Martin, A. R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B. M., & Daly, M. J. (2018) · doi:10.1101/441261 · Cited by 2,813
Genomic prediction of depression risk and resilience under stress
Fang, Y., Scott, L., Song, P., Burmeister, M., & Sen, S. (2019) · Nature Human Behaviour · doi:10.1038/s41562-019-0759-3 · Cited by 43
Genetics of Polycystic Ovary Syndrome
Welt, C. K. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.006 · Cited by 43
Wand, H., Kalia, S. S., Helm, B. M., Suckiel, S. A., Brockman, D., Vriesen, N., Goudar, R. K., Austin, J., & Yanes, T. (2023) · Journal of Genetic Counseling · doi:10.1002/jgc4.1668 · Cited by 45
Significance tests for R2 of out-of-sample prediction using polygenic scores
Momin, M. M., Lee, S., Wray, N. R., & Lee, S. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.01.004 · Cited by 45
Smith, J. L., Tcheandjieu, C., Dikilitas, O., Iyer, K. R., Miyazawa, K., Hilliard, A. T., Lynch, J. A., Rotter, J. I., Chen, Y.-D. I., Sheu, W. H., et al. (2024) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.123.004272 · Cited by 43
Joint impact of polygenic risk score and lifestyles on early- and late-onset cardiovascular diseases
The China Kadoorie Biobank Collaborative Group, Sun, D., Ding, Y., Yu, C., Sun, D., Pang, Y., Pei, P., Yang, L., Millwood, I. Y., Walters, R. G., et al. (2024) · Nature Human Behaviour · doi:10.1038/s41562-024-01923-7 · Cited by 43
Pickering, C., & Kiely, J. (2019) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk4020025 · Cited by 48
Lakeman, I. M. M., Hilbers, F., Rodríguez‐Girondo, M., Lee, A. S., Vreeswijk, M. P. G., Hollestelle, A., Seynaeve, C., Meijers-Heijboer, H. E. J., Oosterwijk, J. C., Hoogerbrugge, N., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106072 · Cited by 43
Bolli, A., Domenico, P. D., Pastorino, R., Busby, G., & Bottà, G. (2021) · Circulation · doi:10.1161/circulationaha.120.051843 · Cited by 44
Polygenic risk score and coronary artery disease: A meta-analysis of 979,286 participant data
Agbaedeng, T. A., Noubiap, J. J., Mato, E. P. M., Chew, D. P., Figtree, G. A., Said, M. A., & van der Harst, P. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.020 · Cited by 46
Muse, E. D., Chen, S., Liu, S., Fernandez, B., Schrader, B., Molparia, B., León, A. N., Lee, R., Pubbi, N., Mejia, N., et al. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00578-w · Cited by 43
Polygenic Risk Scores and Physical Activity
Kujala, U. M., Palviainen, T., Pesonen, P., Waller, K. L., Sillanpää, E., Niemelä, M., Kangas, M., Vähä‐Ypyä, H., Sievänen, H. T., Korpelainen, R., et al. (2020) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002290 · Cited by 46
ROSNER, B. A., Tamimi, R. M., Kraft, P. L., Gao, C., Mu, Y., Scott, C. G., Winham, S. J., Vachon, C. M., & Colditz, G. A. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0900 · Cited by 42
The genetics of non-monogenic IBD
Jans, D. S., & Cleynen, I. (2023) · Human Genetics · doi:10.1007/s00439-023-02521-9 · Cited by 46
Genetic insights into ossification of the posterior longitudinal ligament of the spine
Koike, Y., Takahata, M., Nakajima, M., Otomo, N., Suetsugu, H., Liu, X., Endo, T., Imagama, S., Kobayashi, K., Kaito, T., et al. (2023) · eLife · doi:10.7554/elife.86514 · Cited by 42
Lemche, E., Killick, R., Mitchell, J., Caton, P., Choudhary, P., & Howard, J. K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106485 · Cited by 45
Protein nanoparticles as drug delivery systems for cancer theranostics
Hua, Y., Qin, Z., Gao, L., Zhou, M., Xue, Y., Li, Y., & Xie, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.004 · Cited by 42
Emdin, C. A., Khera, A. V., Aragam, K. G., Haas, M. E., Chaffin, M. D., Klarin, D. M., Natarajan, P., Bick, A. G., Zekavat, S. M., Nomura, A., et al. (2018) · Diabetes · doi:10.2337/db18-0857 · Cited by 42
Self-citationAfrican American ancestry contribution to asthma and atopic dermatitis
Daya, M., & Barnes, K. C. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.02.009 · Cited by 42
Polygenic Scores in Developmental Psychology: Invite Genetics In, Leave Biodeterminism Behind
Raffington, L., Mallard, T. T., & Harden, K. P. (2020) · Annual Review of Developmental Psychology · doi:10.1146/annurev-devpsych-051820-123945 · Cited by 44
Somineni, R. P., Nagpal, S., Venkateswaran, S., Cutler, D. J., Okou, D. T., Haritunians, T., Simpson, C. L., Begum, F., Datta, L. W., Quiros, A., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.02.001 · Cited by 44
Benafif, S., Raghallaigh, H. N., McGrowder, E. H., Saunders, E. J., Brook, M. N., Saya, S., Rageevakumar, R., Wakerell, S., James, D., Chamberlain, A., et al. (2021) · British Journal of Urology · doi:10.1111/bju.15535 · Cited by 42
Miao, Z., Garske, K. M., Pan, D. Z., Koka, A., Kamińska, D., Männistö, V., Sinsheimer, J. S., Pihlajamäki, J., & Pajukanta, P. (2021) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100056 · Cited by 43
Metadata
- Authors
- Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., & Kathiresan, S.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Kathiresan, Sekar
- ORCID
- Venue
- Nature Genetics
- Published
- 2018-08-13
- Volume
- 50
- Issue
- 9
- Pages
- 1219-1224
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC6128408
- OpenAlex
- W2886752110
- Semantic Scholar
- d5eb49c11d070114e2ff46224099895c6b4b1558
- Cited by
- 2,953
- References
- 46
- Citations by year
- 2026: 276 · 2025: 290 · 2024: 363 · 2023: 362 · 2022: 433 · 2021: 411 · 2020: 451 · 2019: 307 · 2018: 57
- FWCI
- 189.86
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Doris Duke Charitable Foundation (2014105)
- Massachusetts General Hospital (HL007208)
- Harvard Catalyst (TR001100)
- Vertex Pharmaceuticals
- KR Foundation
- National Institutes of Health (KL2TR001100, HL0-07734, HL007208, T32-HL007734)
- National Heart, Lung, and Blood Institute (R01HL127564, HL007208, HL127564, R01HL128914, T-32HL007734, K08HL140203, HL007734, K23HL114724, K24HL105780, R01HL142711, R01HL092577, T32HL007208, R01HL139731)
- National Human Genome Research Institute (UM1HG008895)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and phenotypic traits in livestock
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- polygenic risk score, monogenic mutations, common diseases, coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, breast cancer, high-risk individuals, clinical risk stratification
- MeSH terms
- Adult, Aged, Disease, Female, Humans, Male, Middle Aged, Mutation, Risk Factors, Genetic Predisposition to Disease, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
